Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.
Christina M Grassi, Jing Feng, Rahnuma Wahid, Boris Kandinov, Saurabh Goel, Darby Wang, Kristen Sellers, Avika Dixit, Osamu Kogawara, Rituparna Das, Spyros Chalkias
Vaccine 69 127960
摘要
摘要
mRNA-1283 is a next-generation COVID-19 vaccine encoding the immunodominant N-terminal and receptor-binding domains of the SARS-CoV-2 spike protein. This phase 3 randomized, observer-blinded study compared the immunogenicity and safety between monovalent Omicron XBB.1.5-containing formulations of mRNA-1283 (mRNA-1283.815; 10 μg) and mRNA-1273 (mRNA-1273.815; 50 μg) in Japanese participants (≥12 years). The primary objectives were to assess safety and demonstrate the noninferiority of neutralizing antibody response of mRNA-1283.815 versus mRNA-1273.815 against Omicron XBB.1.5 based on the geometric mean ratio (GMR) at Day 29 post-injection (lower bound of 95 % CI, >0.667). Overall, 689 randomly assigned participants received a study vaccine. mRNA-1283.815 was well-tolerated, with no safety concerns identified. mRNA-1283.815 elicited noninferior neutralizing antibody responses to mRNA-1273.815 against Omicron XBB.1.5 at Day 29, meeting the primary immunogenicity objective, with the GMR indicating higher responses of mRNA-1283.815 vs mRNA-1273.815 (GMR [95 % CI], 1.195 [1.028-1.389]). These results support the effectiveness of a monovalent formulation of mRNA-1283.
KM 提取结果
0 个 Figure · 0 个 KM 面板